This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In the IDEAL study, Dr Pedersen and colleagues¹ conclude that intensive cholesterol reduction in patients with prior myocardial infarction can provide benefit without increasing serious adverse effects. However, the incidence of adverse events necessitating permanent discontinuation of high-dose atorvastatin treatment (9.6%) was more than twice that of withdrawal from standard-dose simvastatin (4.2%). In the TNT study, there was also an increase in treatment-related adverse events in patients taking atorvastatin, 80 mg/d, compared with the 10-mg/d regimen (8.1% vs 5.8%; P<.001).² In that study, the number needed to harm of 43 to produce 1 treatment-induced adverse event was similar to the number needed to treat of 45 to produce a reduction in the first cardiovascular event. In the A to Z trial, there was a significantly higher incidence of myopathy with high-dose simvastatin compared with standard therapy.³ Similarly, the incidence of alanine aminotransferase elevation to higher than . . . [Full Text of this Article]

Hean T. Ong, MBBS, FRCP
htyl@streamyx.com
H. T. Ong Heart Clinic
Georgetown, Penang, Malaysia

Jim Seng Cheah, MBBS, FRACP, FRCP
National University of Singapore
Kent Ridge

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

High-Dose Statins and the IDEAL Study
Uffe Ravnskov, Paul J. Rosch, and Morley C. Sutter
JAMA. 2006;295(21):2476.
EXTRACT | FULL TEXT  

High-Dose Statins and the IDEAL Study
William E. Cayley, Jr
JAMA. 2006;295(21):2476.
EXTRACT | FULL TEXT  

High-Dose Statins and the IDEAL Study
Paul S. Chan, Brahmajee K. Nallamothu, and Rodney A. Hayward
JAMA. 2006;295(21):2477.
EXTRACT | FULL TEXT  

High-Dose Statins and the IDEAL Study
Samuel J. Mann
JAMA. 2006;295(21):2477-2478.
EXTRACT | FULL TEXT  

High-Dose Statins and the IDEAL Study—Reply
Terje R. Pedersen, Ole Faergeman, John J. P. Kastelein, Anders G. Olsson, Matti J. Tikkanen, Ingar Holme, Mogens Lytken Larsen, and Fredrik S. Bendiksen
JAMA. 2006;295(21):2478-2479.
EXTRACT | FULL TEXT  

High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial
Terje R. Pedersen, Ole Faergeman, John J. P. Kastelein, Anders G. Olsson, Matti J. Tikkanen, Ingar Holme, Mogens Lytken Larsen, Fredrik S. Bendiksen, Christina Lindahl, Michael Szarek, John Tsai, and for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
JAMA. 2005;294(19):2437-2445.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Which statin, what dose?
DTB 2007;45:33-37.
ABSTRACT | FULL TEXT